Capnodynamic Monitoring of Cardiorespiratory Function in Critically Ill Patients (PROFICIENT)

October 14, 2021 updated by: Anders Aneman, South West Sydney Local Health District

Capnodynamic Monitoring of Cardiorespiratory Function in Patients Admitted to the Intensive Care Unit With COVID-19 Infection, Sepsis and Following Cardiac Surgery

Capnodynamic monitoring has the potential to offer continuous and non-invasive measurements of heart and lung function in patients requiring ventilation in an intensive care setting. Since mechanical ventilation with full patient synchronization is commonly used in ICU, capnodynamic monitoring can be immediately embedded in clinical care and compared to current methods of monitoring cardiac output, lung volumes and oxygen delivery. This observational study will explore capnodynamic monitoring in mechanically ventilated patients with a range of cardiorespiratory compromise.

Study Overview

Detailed Description

This study aims to:

  1. compare the estimation of cardiac output (CO) using the capnodynamic method (COEPBF) with contemporary reference methods;
  2. compare the estimation of mixed venous oxygen saturation (SmvO2) with invasively obtained blood gas analyses;
  3. generate observational data on end-expiratory lung volume (EELV) when ventilator settings, and in particular PEEP, are changed;
  4. combine 1-3 to provide a physiological construct of cardiorespiratory function

Study Type

Observational

Enrollment (Anticipated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • New South Wales
      • Liverpool, New South Wales, Australia, 1871
        • Recruiting
        • Intensive Care Unit, Liverpool Hospital, South Western Sydney Local Health District

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients admitted to ICU for mechanical ventilation with a diagnosis of viral/bacterial pneumonia, sepsis or following cardiac surgery.

Description

Inclusion Criteria:

Respiratory tract infection:

  1. confirmed or highly suspected viral or bacterial pneumonia
  2. meeting ARF or ARDS criteria as outlines in the most recent Berlin ARDS consensus statement
  3. age 18 years or above
  4. arterial and central venous catheters have been inserted or will be inserted as part of routine clinical management
  5. mechanical ventilation via an endotracheal tube is expected to continue for the day beyond day of admission
  6. adequate transthoracic echocardiographic winds are available to measure the velocity time integral in the left ventricular outflow tract
  7. analgosedation is administered as part of routine management of residual neuromuscular blockaded initiated outside ICU OR the administration of analgosedation and/or neuromuscular blockers at doses that achieve full patient-ventilator synchrony are considered part of routine clinical management

Sepsis:

  1. admitted to ICU with a provisional or established diagnosis of septic shock as defined by the Sepsis-3 criteria
  2. age 18 years or above
  3. arterial and central venous catheters have been inserted or will be inserted as part of routine clinical management
  4. mechanical ventilation via an endotracheal tube is expected to continue for at least another two hours
  5. adequate transthoracic echocardiographic winds are available to measure the velocity time integral in the left ventricular outflow tract
  6. analgosedation is administered as part of routine management of residual neuromuscular blockaded initiated outside ICU OR the administration of analgosedation and/or neuromuscular blockers at doses that achieve full patient-ventilator synchrony are considered part of routine clinical management
  7. the administration of a fluid bolus (250 ml or 500 ml) is indicated as judged by the medical officer supervising routine management

Cardiac surgery:

  1. admitted to ICU following cardiac surgery using cardiopulmonary bypass
  2. age 18 years and above
  3. arterial, central venous and pulmonary arterial catheters have been inserted or will be inserted as part of routine clinical management
  4. mechanical ventilation via an endotracheal tube is expected to continue for at least another two hours
  5. analgosedation is administered as part of routine management of residual neuromuscular blockade initiated intraoperatively OR the administration of analgosedation and/or neuromuscular blockers at doses that achieve full patient-ventilator synchrony are considered part of routine clinical management
  6. the administration of a fluid bolus (250 ml or 500 ml) is indicated as judged by the medical officer supervising routine postoperative management

Exclusion Criteria:

In all cohorts:

  1. age under 18 years
  2. known pregnancy
  3. arterial and central venous catheters are not indicated as part of routine care
  4. known severe valvulopathy
  5. ongoing or imminent need for mechanical circulatory support
  6. severe haemodynamic instability with imminent transfer for intervention(s) outside ICU
  7. patient is not for full active management in ICU
  8. patient is not expected to live beyond the day of admission
  9. patient is re-admitted to ICU within the same index hospital admission
  10. it is not possible to achieve full patient-ventilator synchrony

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Respiratory tract infection
Patients diagnosed with viral or bacterial pneumonia and admitted to ICU for mechanical ventilatory support

In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:

ELV x [(FACO2(n)-FACO2(n-1)] = delta(n) x EPBF [CvCO2(n)] - VTCO2.

Other Names:
  • echocardiography
  • thermodilution cardiac output measurement
  • blood gas analyses
Sepsis
Patients diagnosed with sepsis and admitted to ICU for mechanical ventilatory support

In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:

ELV x [(FACO2(n)-FACO2(n-1)] = delta(n) x EPBF [CvCO2(n)] - VTCO2.

Other Names:
  • echocardiography
  • thermodilution cardiac output measurement
  • blood gas analyses
Cardiac surgery
Patients admitted to ICU for mechanical ventilatory support following cardiac surgery

In patients fully synchronized with mechanical ventilation, the capnodynamic method calculates the effective pulmonary blood flow, the end-expiratory lung volume and estimates the mixed venous oxygen saturation. The capnodynamic method uses short inspiratory or expiratory pauses to induce small changes in CO2 concentration the enable the mole balance to be resolved for the capnodynamic equation:

ELV x [(FACO2(n)-FACO2(n-1)] = delta(n) x EPBF [CvCO2(n)] - VTCO2.

Other Names:
  • echocardiography
  • thermodilution cardiac output measurement
  • blood gas analyses

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation between capnodynamic effective pulmonary blood flow and cardiac output measured by pulmonary artery thermodilution or echocardiography
Time Frame: Through study completion, an average of 1 year
Capnodynamic measurements of effective pulmonary blood flow are compared with contemporaneously obtained cardiac output measurements using clinical reference methods
Through study completion, an average of 1 year
Correlation between capnodynamic estimates of mixed venous oxygen saturation and blood gas analysis of blood obtained from the pulmonary artery pulmonary.
Time Frame: Through study completion, an average of 1 year
Capnodynamic estimates of mixed venous oxygen saturation are compared with contemporaneously obtained blood gases from the pulmonary artery catheter
Through study completion, an average of 1 year
Prediction by capnodynamic monitoring of combined changes in end expiratory lung volume and effective pulmonary blood flow to assess changes in pulmonary gas exchange during various levels of PEEP
Time Frame: Through study completion, an average of 1 year
At three different levels of PEEP, the interactions between end expiratory lung volume and effective pulmonary blood flow will be assessed and correlated to changes in arterial partial pressure of oxygen and carbon dioxide
Through study completion, an average of 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2021

Primary Completion (Anticipated)

December 31, 2022

Study Completion (Anticipated)

July 1, 2023

Study Registration Dates

First Submitted

September 20, 2021

First Submitted That Met QC Criteria

October 14, 2021

First Posted (Actual)

October 18, 2021

Study Record Updates

Last Update Posted (Actual)

October 18, 2021

Last Update Submitted That Met QC Criteria

October 14, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Upon reasonable request, IPD may be shared if fully compliant with HREC requirements and European GRDP regulations

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sepsis

Clinical Trials on Capnodynamic monitoring

Subscribe